You don't have to be a technical person to know that the 4.40's is a MAJOR resistance point, inflection point, whatever you want to call it. Best of luck!
You won't stoop to clueless conjecture, but you will stoop to clueless denigration of people's right to free speech.
I cannot believe that a post of mine would get the famously cheese impacted colon himself to come crawling out, like tapeworm trying to escape the anthelmintic.
Still have faith in the concept, but a PR announcing 65 patients enrolled, when we were actually expecting "top line results", promised by the end of Q2??????????
The trial may enroll very quickly because the word is out on Imetelstat.
A patient doesn't usually get to see brochures from the Mayo clinic about a drug's effectiveness before signing up for a Phase II trial.
If you had MF and had done any research at all on your own, wouldn't you be asking where and when you can sign up?
Smart investors buying in anticipation of imminent official announcement of trial commencement.
Predict a small Pop upon announcement, and a Big Pop when trial is fully enrolled, which will come soon after. But the real victory pay off will come next winter.
Congratulations to all the persistent ones. Compared to what we've been through so far, this next leg of the journey seem like the blink of an eye.
Currently high on a similar victory (Novavax), that has shown me how good it can feel.
Uremic pruritis is a special kind of "itch" as I understand it. pertaining exclusively to hemodialysis patients. I'm hoping that the top line data is positive for CARA, as it prepares to conduct the PH III studies on their non-addictive pain reliever. I'm trying to trade this stock, but I'm wondering if I shouldn't instead be accumulating it for the possibility of a buyout.
US, sites in 10 states, CA 3, NY 3, IL 1, MD 1, MI 1, MO 1, NC 1, PA 1, TX 1, WA 1,
Belgium 2, France 6, Germany 8, Spain 1, Taiwan 2.
And/Or, (FYI, I'm long ONTY, not bashin', just sayin'), certain entities will take a huge short position and sit on the stock for a while. Newbies should exercise caution.
What has happeed with ONTY as ASCO is a good example of how rapidly things can change.